Frost & Sullivan Recognizes Medtronic Diabetes’ Technology Leadership in the Glucose Management Market

Frost & Sullivan Recognizes Medtronic Diabetes’ Technology Leadership in the Glucose Management Market

PALO ALTO, Calif. — Frost & Sullivan’s recent study, Strategic Analysis of the World Diabetes Glucose Self Monitoring Devices Markets, acknowledged Medtronic Diabetes’ exceptional platform, CGMS(R) System Gold(TM), for providing continuous blood sugar monitoring information to physicians for improved diabetes management.

While fingerstick readings using a traditional meter is the standard for monitoring blood sugar levels, the absence of continuous glucose data can be considered a hindrance to physicians in effectively evaluating and treating diabetes. That’s because standard fingerstick readings, as well as hemoglobin A1c tests, do not always expose erratic blood sugar patterns that contribute to diabetes-related complications, including blindness, kidney failure, amputations, impotence and heart disease.

CGMS(R) System Gold(TM) provides physicians with detailed blood sugar information in the form of charts and graphs, enabling them to review glucose trends and refine therapy for the patients they treat. The system’s glucose sensor continuously monitors blood sugar levels in patients for up to three days. “The technology reveals hidden blood sugar patterns such as hypoglycemia — which can be very dangerous for diabetes patients,” says Frost & Sullivan Research Analyst Seemeen Mirza. The retrospective data provided by the CGMS(R) System Gold(TM) enables healthcare providers to make more informed treatment decisions for any diabetes patient, regardless if they have type 1 or type 2 diabetes.

Medtronic Diabetes is a pioneer in the field of continuous glucose monitoring systems. The company’s vision is to integrate its CGMS(R) System Gold(TM) technology with its insulin pumps to create “sensor-augmented” therapy systems and, ultimately, an artificial pancreas.

For its sound technology innovation in the healthcare industry, Medtronic is presented with the 2004 Technology Leadership Award by Frost & Sullivan. This award is presented each year to the company that has successfully developed new technologies and been the first-to-market with them. The technology has also seen increased adoption rates due to its efficacy, thereby establishing the company as a technology leader.

“Hundreds of clinical articles support the use of CGMS System Gold,” notes Mirza. “This bodes well for integrated systems, which are expected to simplify diabetes management and improve patients’ blood sugar control, thereby improving health and extending life for people with the disease.”

About Medtronic Diabetes

Medtronic Diabetes (www.minimed.com) is the world leader in insulin pump therapy and continuous glucose monitoring systems. The company’s products include external insulin pumps, related disposable products, and continuous glucose monitoring systems. Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the world’s leading medical technology company, providing lifelong solutions for people with chronic disease.

About Frost & Sullivan

Founded in 1961, Frost & Sullivan is recognized as a global leader in growth consulting. Frost & Sullivan Awards are presented to companies that demonstrate excellence in their industry, commending the diligence, commitment, and innovative business strategies required to advance in the global marketplace. Frost & Sullivan rigorously analyzes specific criteria to determine award recipients in a vast variety of market industries and landscapes. For further information, visit www.frost.com.

COPYRIGHT 2004 Business Wire

COPYRIGHT 2004 Gale Group